Survival Outcomes in Renal Transplant Recipients With Renal Cell Carcinoma or Transitional Cell Carcinoma From the ANZDATA Database
|
|
- Ashlyn Heath
- 5 years ago
- Views:
Transcription
1 ARTICle Survival Outcomes in Renal Transplant Recipients With Renal Cell or Transitional Cell From the ANZDATA Database Weranja K. B. Ranasinghe, 1,3 Nancy Suh, 1,2,3 Peter D. Hughes 2,3 Abstract Objectives: Our objective was to determine the incidence and outcomes of renal cell carcinoma and transitional cell carcinoma in recipients of renal allografts. Materials and Methods: We analyzed data from 2000 to 2012 in the Australia and New Zealand Dialysis and Transplant Registry, a binational population-based database, to identify the incidence and survival outcomes of renal transplant recipients with renal cell and transitional cell carcinoma. Results: Of the 8850 renal transplants, there were 60 new diagnoses of renal cancers posttransplant, with an overall cumulative incidence of 56 per per year. Nine tumors were detected in the allograft, and 51 tumors (85%) were detected in the native kidney of the recipient. The median time of diagnosis from transplant was 6.6 years (range, y). There were no cancerspecific deaths from allograft tumors; however, 17 cancer-specific deaths (14 from renal cell carcinoma and 3 from transitional cell carcinoma) occurred in patients with cancer in the native kidney. The 5-year and 10-year cancer-specific survival rates for renal cell carcinoma were 71.2% (95% confidence interval (CI): ) and 58.5% (95% CI: ), with 5-year and 10-year rates for transitional cell carcinoma of 50% (95% CI: ) and 0%. Conclusions: Renal cell carcinoma occurring in the native kidney comprised most of the tumors detected after renal transplant; however, transitional cell carcinoma occurred sooner after transplant and resulted in a lower cancer-specific survival rate. While it is important to From the 1 Monash Medical Centre; the 2 Royal Melbourne Hospital, Melbourne, Victoria, Australia; and the 3 ANZDATA Registry, Adelaide, South Australia, Australia Acknowledgements: The authors have no conflicts of interest to declare. We acknowledge the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) for providing the data and statistical support. The data reported here have been supplied by ANZDATA. The interpretation and reporting of these data are the responsibility of the editors and in no way should be seen as an official policy or interpretation of the Australia and New Zealand Dialysis and Transplant Registry. Corresponding author: Weranja K. B. Ranasinghe, Department of Urology, Monash Medical Centre, Centre Road, Bentleigh, Victoria, Australia 3165 Phone: Fax: weranja@gmail.com Experimental and Clinical Transplantation (2016) 2: screen those at risk of TCC prior and after renal transplant, the low incidence of TCC maybe too small to justify a benefit with routine screening, compared to RCCs. Key words: Cancer, Incidence, Screening Introduction Transplant is the optimal treatment for end-stage kidney disease, improving both survival and quality of life. 1 Although improvements in immuno - suppressive medications have resulted in an increase in the number of patients living with a functioning renal allograft, different causes of morbidity and mortality in transplant patients have also emerged. Malignancy has now become the most common cause of death for patients with a functioning graft, followed by cardiovascular disease. 2 The risk of malignancy is increased in transplant recipients by 3- to 4-fold over the rate seen in the general population. Renal cell carcinoma (RCC) is the most common solid-organ malignancy after kidney transplant and has previously been estimated to be increased by approximately to 7.97-fold com pared with that shown in the general population. 3-8 When compared with RCC, the rates of transitional cell carcinoma (TCC) after transplant are lower, with an incidence of 2%. 9 Presently, comparisons in the literature of the incidence and survival of RCC and urothelial carcinoma or TCC in recipients of renal allografts are limited. We aimed to determine the incidence of RCC and TCC in recipients of a renal transplant using a large binational population-based database and to examine the differences in the cancer-specific survival rates in these patients in both the native kidneys and allografts. The potential uses of screening for urinary tract malignancy after kidney transplant are also discussed. Copyright Başkent University 2016 Printed in Turkey. All Rights Reserved. DOI: /ect
2 Weranja K. B. Ranasinghe et al/experimental and Clinical Transplantation (2016) 2: Materials and Methods The Australia and New Zealand Dialysis and Transplant Registry is a population-based database of all patients who start maintenance dialysis or receive kidney transplant in Australia or New Zealand. Data are collected in accordance with the ANZDATA privacy policy in which only anonymized data are released by the registry to researchers. Data are collected in accordance with the Australian Commonwealth Privacy Act, and individual patient consent is not required for the registry data. Patient anonymity is maintained by the coding of data during compilation; only anonymized data are released by the registry to researchers. 10 Data from the Australia and New Zealand Dialysis and Transplant Registry have been validated previously and shown to be comparable with other transplant registries around the world. 11 All new diagnoses of RCC and TCC in patients who received kidney transplants between 2000 and 2012 were identified using the International Classification of Diseases 10 codes. We collected data on patients who had cancer development in the allograft or the native kidney. The follow-up was calculated as time from tumor diagnosis until The incidence rates, the time from transplant to the development of cancer, and survival rates for each type of cancer were also calculated. The overall cumulative incidence was calculated per persons for the 12 years. The median time to diagnosis and survival rates were calculated using Kaplan-Meier estimate. Cumulative incidence was used to analyze cancer-specific survival to allow for competing risk (of death from other causes). We used Stata/IC (StataCorp Stata Statistical Software: Release 13. College Station, TX, USA) for statistical analyses. Results There were 8850 renal transplants during the period of analyses from 2000 to Of these, 3347 were living-donor kidney transplants, 4916 were kidneys from donors after brain death, and 587 were kidneys from donors after cardiac death. Of 8850 renal transplants, 7788 were first transplants, and 1062 were repeat transplants. During the period of analyses, 60 new diagnoses of renal cancer posttransplant were made, with 85% of these tumors developing in the recipient s native kidney. The overall incidence for all renal tumors was 56 per per year. Most tumors were found in male patients (85%), and mean age at detection was 55.9 years. The proportion of tumors was slightly higher in recipients of kidneys from brain dead donors (58.3%) than in patients receiving living-donor kidney transplants (41.7%) (Table 1). There were no reported renal tumors in recipients who received kidneys from donors after cardiac death. The overall incidence of RCC was 52 per , and the overall incidence of TCC was 5 per per year. There were no patients with RCC or TCC who were lost to follow-up in this cohort. Table 1. Cancer Incidence in the Native Kidney and Allograft After Kidney Transplant Number of Patients Total Renal Cell Transitional Cell Renal cancer after transplant Type of transplant Living donor Brain dead donor Cardiac death donor 0 Sex Male Female Age at diagnosis (y) > Median time from any transplant (y) 4.5 (range, ) 2.1 (range, ) Median time from 1st transplant (y) 5.6 (range ) 2.1 (range, ) Tumors in the graft kidney Nine tumors were detected in allografts post - transplant. Eight of these tumors were RCC, and 1 was TCC. Most of the patients in this group were males (7/9) with kidney donations from brain dead donors. The average age of patients who developed cancer in the allograft was 48.8 years, and the median time from transplant to cancer diagnosis was 6.6 years, with the earliest being detected at 0.1 years (1.2 mo) after transplant (range, y) (Table 2). Tumors in the native kidney Fifty-one tumors were detected in native kidneys posttransplant, with 47 of these being RCCs. Most patients who in this group were men (86%), and the average age at diagnosis was 57.1 years. In patients who developed tumors in the native kidney, 45% had
3 168 Weranja K. B. Ranasinghe et al/experimental and Clinical Transplantation (2016) 2: Exp Clin Transplant received a kidney donation from a living donor, whereas 55% received a kidney donation from a brain dead donor; 53% of patients developed tumors on the left kidney. Transitional cell carcinomas were seen in recipients older than 50 years, with a higher percentage shown in recipients who received a donation from a brain dead donor (75%). The earliest time from transplant to detection was 0.02 years (0.24 mo), with median time to TCC occurrence of 1.9 years and median time to RCC occurrence of 4.3 years (Table 3). Survival rates for patients with renal tumors posttransplant In our patient group, 22 deaths occurred in patients diagnosed with renal cancer during follow-up, of which 17 were cancer specific. The 5 deaths not attributed to cancer were from cardiac events and electrolyte imbalances (Figure 1). The overall 10-year survival rate was 42.9% (95% CI, ) (Figure 2), Table 2. Cancer Incidence in the Native Kidney and Allograft After Kidney Transplant Number of Patients Total Renal Cell Transitional Cell Renal cancers after transplant Type of transplant Living donor Brain dead donor Sex Male Female Age at diagnosis (y) > Mean age (y) Median time from any transplant (y) 6.6 (range, ) 6.9 (range ) Table 3. Cancer Incidence in Native Kidneys After Renal Transplant Number of Patients Total Renal Cell Transitional Cell Renal cancer after transplant Type of transplant Living donor Brain dead donor Sex Male Female Age at diagnosis (y) > Mean age (y) Median time from any transplant (y) 4.3 (range, ) 1.9 (range, ) Median time from 1st transplant (y) 5.4 (range, ) 1.9 (range, ) and the cancer-specific survival rate was 42.2% (95% CI, ). In patients who developed tumors in the allograft, there was only 1 death in a patient with RCC; however, this was from a cardiac event during the follow-up of 9.2 years. Survival rates for patients with cancer in the native kidney In contrast to patients with tumors that developed in the allograft, all 17 cancer-specific deaths were in patients with tumors in the native kidneys. The 5-year and 10-year overall survival rates for patients with cancer in the native kidney were 59.1% (95% CI, ) and 37.6% (95% CI, ) (Figure 2). The cancer-specific (RCC or TCC) survival rates for patients with cancer in the native kidney was 68.2% at 5 years (95% CI, ) and 51.5% at 10 years (95% CI, ) (Figure 2). Of the 17 cancer-specific deaths of patients with cancer in the native kidney, 14 were from RCC and 3 were from TCC (Figure 1). The survival rate for Figure 1. Overall Number and Cause of Death in Patients with Renal Malignancy (in Native Kidney and Allograft) After Renal Transplant (A) Cause of death in all patients diagnosed with a malignancy in native kidney or allograft. (B) Cause of death in patients with a malignancy in native kidney. (C) Number of patients with renal cell carcinoma and transitional cell carcinoma by cause of death in the native kidney.
4 Weranja K. B. Ranasinghe et al/experimental and Clinical Transplantation (2016) 2: Figure 2. Overall Survival After Renal Transplant (A) Overall survival in patients diagnosed with renal cell carcinoma or transitional cell carcinoma in either native kidney or allograft from date of renal transplant. (B) Overall survival in patients with renal cell carcinoma or transitional cell carcinoma in the native kidney from the date of transplant. (C) Overall survival in patients with renal cell carcinoma or transitional cell carcinoma in the allograft from the date of transplant. patients who developed RCC in the native kidney was 71.2% at 5 years (95% CI, ) and 58.5% at 10 years (95% CI, ). In contrast, the 5- and 10-year survival rates for TCC were 50% (95% CI, ) and 0%. Discussion The overall incidence of renal cancer after transplants was 56 per per year for recipients in our study. The median time from transplant to development of any renal cancer was 4.5 years for RCC and 2.1 years for TCC. Although other studies have demonstrated that a higher proportion of tumors occur in the native kidney, 12,13 our results demonstrate that the median times for development of both RCC and TCC in the native kidney were much shorter than in the allograft. In contrast to our findings, other studies have shown a longer median time of 3.9 to 7.4 years for development of RCC and 4.4 to 4.8 years for TCC after renal transplant. 14,15 However, our results demonstrate that some cancers were detected as early as 1 month and as late as 12.2 years after transplant. The cause for the shorter interval between transplant and diagnosis of renal cancer, particularly TCC, versus that shown in other reports is unclear. This could relate to differences in testing and screening both before and after transplant in the different populations, in particular regarding the difficulty in detection of TCC. Transitional cell carcinoma can present with painless macroscopic or microscopic hematuria, repeated urologic infection, or asymptomatic hydronephrosis during a routine examinations. 16 Upper renal tract TCCs can be difficult to diagnose in the general population, even with the use of contrast computed tomography and cytology. The diagnosis of TCC in native kidneys in the transplant population is even more difficult. This is partly because of a reluctance to use contrast-enhanced computed tomography to avoid contrast-induced nephropathy and the limited opacification of any luminal lesions due to reduced excretion of contrast from poorly functioning native kidneys. The European Association of Urology guidelines recommend the use of cytology in patients with microhematuria, analgesic nephropathy, or previous history of urothelial carcinoma. 17 However, results from urine cytology, which is often used in the general population, also are affected by the limited function of native kidneys of transplant patients. These pose significant challenges in the diagnoses of TCCs in native kidneys, both before and after and transplant. Unlike RCC, the rates of TCC after transplant are lower, with an incidence of 2%, 9 although this incidence appears to be altered less by immunosuppressive medications. 8,18 However, in patients diagnosed with TCC, a previous transplant is also associated with poorer outcomes. 19 Because our aim was to investigate the incidence of these malignancies, risk factors, including the length of immunosuppression, were not formally investigated. Cigarette smoking, hypertension, obesity, and family history are well-established risk factors for RCC. In addition, the risk of developing of RCC has been shown to be increased with greater duration of end-stage kidney disease and by the development of
5 170 Weranja K. B. Ranasinghe et al/experimental and Clinical Transplantation (2016) 2: Exp Clin Transplant acquired cystic disease. 20 Therefore, improvements in allograft and recipient outcomes, with longer survival after reaching end-stage kidney disease, are likely to be associated with further increases in the occurrence of RCC. 6 The survival rate of patients diagnosed with malignancy after transplant, including RCC, also appears to be lower than the general population. 19 Despite the increased incidence and poor outcomes after kidney transplant, no trials assessing the role of screening for RCC in this population have been conducted and previous attempts to model the performance of screening by ultrasound were not shown to be cost effective. 21 The current recommendations of the European Association of Urologists for screening of renal cancer in transplant patients suggest annual screening of the allografts and native kidneys to detect renal tumors. 17 However, the American Society of Transplantation and the Kidney Disease Improving Global Outcomes Clinical Practice Guidelines for the Care of the Kidney Transplant Recipient do not recommend routine screening for renal cancers after transplant. 22 Although routine annual ultrasonographic screening for renal cancer may improve survival by up to 25%, it has not shown to be cost effective for transplant recipients, even for those at high risk of disease. 21 Some of the underlying limitations in use of ultrasonography as a screening tool are user dependence, lower sensitivity and specificity in detecting small tumors (< 3 cm), and uncertain performance in the presence of cystic kidney disease and small scarred kidneys, which are commonly present in patients with chronic kidney disease. 21 Contrast-enhanced computer tomography scans have risks of contrast-induced nephropathy and acute kidney injury. 21 Compared to a previous study that used the Australia and New Zealand Dialysis and Transplant Registry in 2008, which demonstrated a cumulative incidence of 46 per per year, our results, updated until 2012, show a 17.8% increase in kidneyrelated tumors. 23 Although this is a small change in the incidence of RCCs and TCCs after transplant, this increase, along with the poor survival rates, suggests a possible benefit in the use of screening in this population. One of the main findings of our study was the large proportion of tumors detected in the native kidneys and the lower survival rates versus for tumors detected in the allograft. In addition to the reasons discussed previously, the better prognosis in the allograft also could result from closer monitoring of the allograft with a low threshold for biopsies, contributing to early detection and improved survival rates with graft excision. Our study used a large, validated, binational population-based database that identified a large number of cancers. However, the retrospective nature of the study and other limitations inherent to database registries could have influenced our results. The registry does not capture the TNM staging, Fuhrman grade, and histologic subtype of kidney tumors or treatment, which are significant limitations. Therefore, we were unable to determine which patients were symptomatic from the disease or whether any of these tumors were found incidentally or through screening programs. We were also not aware of what modality was used to detect the cancers, the stage at the time of diagnosis, or the treatments used. We aim to address this in a future study of the characteristics of the tumors and treatment modalities in a subsection of cancer patients from the Australia and New Zealand Dialysis and Transplant Registry. Conclusions Our study demonstrates an overall incidence of 56 per per year of renal tumors in transplant recipients, with most being RCCs detected in the native kidneys. However, in our patient cohort, TCCs occurred in the native kidneys earlier after transplant than RCCs and were associated with a lower survival rate. The cancer-specific mortality in patients with renal cancer posttransplant is high, particularly for tumors in the native kidneys, possibly because of a later diagnosis compared to cancers in the allograft. References 1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23): doi: /NEJM ANZDATA. ANZDATA Registry Report th ed. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry. 35th Report/2012_annual_report.pdf. Published Accessed June 15, Kyllonen L, Salmela K, Pukkala E. Cancer incidence in a kidneytransplanted population. Transpl Int. 2000;13 Suppl 1:S394-S Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet. 2000;355(9218):
6 Weranja K. B. Ranasinghe et al/experimental and Clinical Transplantation (2016) 2: Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7): doi: /sj.bjc Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23): doi: /jama Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7(4): doi: /j x. 8. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immuno - suppressed transplant recipients: a meta-analysis. Lancet. 2007; 370(9581): doi: /S (07) Yang TC, Shu KH, Cheng CH, Wu MJ, Lian JD. Malignancy following renal transplantation. Zhonghua Yi Xue Za Zhi (Taipei). 1998;61(5): ANZDATA. Data collection, Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry. Published Accessed April McDonald SP, Russ GR. Australian registries-anzdata and ANZOD. Transplant Rev (Orlando). 2013;27(2): doi: /j.trre Penn I. Primary kidney tumors before and after renal transplantation. Transplantation. 1995;59(4): Heinz-Peer G, Schoder M, Rand T, Mayer G, Mostbeck GH. Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study. Radiology. 1995;195(3): doi: /radiology Melchior S, Franzaring L, Shardan A, et al. Urological de novo malignancy after kidney transplantation: a case for the urologist. J Urol. 2011;185(2): doi: /j.juro Hevia V, Gomez V, Diez Nicolas V, et al. Development of urologic de novo malignancies after renal transplantation. Transplant Proc. 2014;46(1): doi: /j.transproceed Li XB, Xing NZ, Wang Y, Hu XP, Yin H, Zhang XD. Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol. 2008;15(1): doi: /j x. 17. Karam G, Kälble T, Alcaraz A, et al. Guidelines on Renal Transplantation. Arnhem, The Netherlands: European Association of Urology, Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6): doi: /j x. 19. Miao Y, Everly JJ, Gross TG, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation. 2009;87(9): doi: /TP.0b013e3181a238f Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5): doi: / nrurol Wong G, Howard K, Webster AC, Chapman JR, Craig JC. Screening for renal cancer in recipients of kidney transplants. Nephrol Dial Transplant. 2011;26(5): doi: /ndt/gfq Kidney Disease: Improving Global Outcomes Transplant Work. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-S155. doi: /j x. 23. Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the evidence? Clin J Am Soc Nephrol. 2008;3(suppl 2):S87-S100. doi: /CJN
Chapter 10. Cancer. ANZDATA gratefully acknowledges the contributions of the Cancer Working Group convened by Germaine Wong.
Chapter Cancer ANZDATA gratefully acknowledges the contributions of the Cancer Working Group convened by Germaine Wong Contents: Cancer -1 Incidence of Cancer on Renal Replacement Therapy -2 Kidney Cancer
More informationChapter 10. Cancer. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015
Chapter Cancer 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Incidence of Cancer on Renal Replacement Therapy Figures.1-.6 and table.1 show the cumulative incidence of non-skin cancer in patients
More informationDonor-Transmitted, Donor-Derived, and De Novo Cancer After Liver Transplant
Lecture Donor-Transmitted, Donor-Derived, and De Novo Cancer After Liver Transplant Jeremy R. Chapman, 1 Stephen V. Lynch 2 Abstract Cancer is the third most common cause of death (after cardiovascular
More informationAustralia & New Zealand Pancreas. Transplant Registry Report Inquiries or comments should be directed to the secretariat at:
Australia & New Zealand Pancreas Transplant Registry Report 1984-2013 This report is a compilation of data provided by the four current Pancreas transplant units in Australia and New Zealand: Auckland
More informationCancer Incidence Among Canadian Kidney Transplant Recipients
American Journal of Transplantation 2007; 7: 941 948 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationAustralia & New Zealand Pancreas. Transplant Registry Report
Australia & New Zealand Pancreas Transplant Registry Report 1984-2007 This report is a compilation of data provided by the five current Pancreas transplant units in Australia and New Zealand: Auckland
More informationNative Renal Cysts and Dialysis Duration Are Risk Factors for Renal Cell Carcinoma in Renal Transplant Recipients
American Journal of Transplantation 2011; 11: 86 92 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationSurvival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand,
Nephrol Dial Transplant (2002) 17: 2212 2219 Original Article Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationSHORT COMMUNICATION. G. Joshy & P. Dunn & M. Fisher & R. Lawrenson
Diabetologia (2009) 52:1474 1478 DOI 10.1007/s00125-009-1380-1 SHORT COMMUNICATION Ethnic differences in the natural progression of nephropathy among diabetes patients in New Zealand: hospital admission
More informationKidney transplantation 2016: current status and potential challenges
Kidney transplantation 2016: current status and potential challenges 15/12/2016 BVN-SBN : State-of-the-Art on Kidney Transplantation Patrick Peeters Ghent University Hospital, Belgium Challenges in 2016
More informationRenal cell carcinoma of the native kidney in a renal transplant recipient
www.edoriumjournals.com CLINICAL IMAGES PEER REVIEWED OPEN ACCESS Renal cell carcinoma of the native kidney in a renal transplant recipient Vikrampal Bhatti, Ananthalaxmi Vangapalli, Deepti Bhattacharya,
More informationShort-term and Long-term Survival of Kidney Allograft Cure Model Analysis
TRANSPLANTATION Short-term and Long-term Survival of Kidney Allograft Cure Model Analysis Moghaddameh Mirzaee, 1 Jalal Azmandian, 2 Hojjat Zeraati, 1 Mahmood Mahmoodi, 1 Kazem Mohammad, 1 Abbas Etminan,
More informationMalignancies after renal transplantation in Taiwan: a nationwide population-based study
Nephrol Dial Transplant (2012) 0: 833 839 doi: 10.1093/ndt/gfr277 Advance Access publication 1 June 2011 Malignancies after renal transplantation in Taiwan: a nationwide population-based study Wei-Hsuan
More informationDiabetes Mellitus GUIDELINES UNGRADED SUGGESTIONS FOR CLINICAL CARE IMPLEMENTATION AND AUDIT BACKGROUND
Diabetes Mellitus Date written: November 2011 Author: Scott Campbell GUIDELINES a. We recommend that diabetes should not on its own preclude a patient from being considered for kidney transplantation (1D).
More informationComparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population
DOI 10.1007/s10147-015-0812-9 ORIGINAL ARTICLE Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population Yasunobu
More informationThyroid cancer and renal transplantation: a meta-analysis
Thyroid cancer and renal transplantation: a meta-analysis Dheeraj Karamchandani 1, Ramiro Arias-Amaya 3, Nora Donaldson 3, Jackie Gilbert 3 and Klaus-Martin Schulte 1,2 1 Department of Endocrine Surgery,
More informationIncidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review
Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Jessica Ludolph 1 Lynsey Biondi, MD 1,2 and Michael Moritz, MD 1,2 1 Department of Surgery,
More informationQuantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons Quantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
More informationRenal Tumors in Transplantation
Renal Tumors in Transplantation Kevin Morrison Clinical-Pathological Correlation September 15 th, 2004 Overview Case reports Neoplasia in transplantation Renal allograft tumors Native kidney RCC Role of
More informationKidney Transplant Outcomes In Elderly Patients. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
Kidney Transplant Outcomes In Elderly Patients Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Case Discussion 70 year old Asian male, neuropsychiatrist, works full
More informationAllocation of deceased donor kidneys. Phil Clayton NSW Renal Group 14 June 2012
Allocation of deceased donor kidneys Phil Clayton NSW Renal Group 14 June 2012 Outline Why study kidney allocation? Equity vs utility Current Australian model Previous work in Australia US allocation research
More informationJamalbek Ashimov, Janybek Gaibyldaev SRI of Heart Surgery and Organ Transplantation, Bishkek, Kyrgyzstan
Brief Report Types and structure of complications, and causes of mortality with different combinations of immunosuppressants in patients of undergoing organ transplantation Jamalbek Ashimov, Janybek Gaibyldaev
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 5. Classification of chronic kidney disease based on evaluation of kidney function
5. Classification of chronic kidney disease based on evaluation of kidney function Date written: April 2005 Final submission: May 2005 GUIDELINES No recommendations possible based on Level I or II evidence
More informationChapter 7. Australian Waiting List. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015
Chapter 7 Australian Waiting List 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Stock and Flow The waiting list data reported here are derived from the Australian National Organ Matching System
More informationLong-Term Survival of Children with End-Stage Renal Disease
The new england journal of medicine original article Long-Term of Children with End-Stage Renal Disease Stephen P. McDonald, Ph.D., and Jonathan C. Craig, Ph.D., for the Australian and New Zealand Paediatric
More informationF. Branco, V. Cavadas, L. Osório, F. Carvalho, L. Martins, L. Dias, A. Castro-Henriques, and E. Lima
The Incidence of Cancer and Potential Role of Sirolimus Immunosuppression Conversion on Mortality Among a Single-Center Renal Transplantation Cohort of 1,816 Patients F. Branco, V. Cavadas, L. Osório,
More informationLong-Term Renal Allograft Survival in the United States: A Critical Reappraisal
American Journal of Transplantation 2011; 11: 450 462 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Analgesic-Associated Kidney Disease GUIDELINES
Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas Analgesic-Associated Kidney Disease GUIDELINES a. Analgesic intake should be discontinued in patients with analgesic nephropathy.
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationChapter 9. Kidney Donors. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015
Chapter 9 Kidney Donors 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Deceased Kidney Donors The data for this section come from the Australia and New Zealand Organ Donor (ANZOD) Registry.
More informationCase Report De Novo Renal Cell Carcinoma in a Kidney Allograft 20 Years after Transplant
Case Reports in Transplantation Volume 2015, Article ID 679262, 4 pages http://dx.doi.org/10.1155/2015/679262 Case Report De Novo Renal Cell Carcinoma in a Kidney Allograft 20 Years after Transplant Masataka
More informationClinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma Associated with End-stage Renal Disease
Jpn J Clin Oncol 2014;44(11)1096 1100 doi:10.1093/jjco/hyu117 Advance Access Publication 19 August 2014 Clinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma
More informationBurden of end-stage renal disease
Summary of Indigenous health: End-stage renal disease Neil Thomson and Sasha Stumpers Australian Indigenous HealthInfoNet, Edith Cowan University www.healthinfonet.ecu.edu.au This summary of end-stage
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationEffect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations
NDT Advance Access published November 9, 2005 Nephrol Dial Transplant (2005) 1 of 8 doi:10.1093/ndt/gfi248 Original Article Effect of previously failed kidney transplantation on peritoneal dialysis outcomes
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationHeart/Lung Transplant
Medical Policy Manual Transplant, Policy No. 03 Heart/Lung Transplant Next Review: March 2019 Last Review: April 2018 Effective: June 1, 2018 IMPORTANT REMINDER Medical Policies are developed to provide
More informationCancer in kidney transplant recipients: epidemiology and prevention
BTS 2018, Brighton Cancer in kidney transplant recipients: epidemiology and prevention Adnan Sharif Queen Elizabeth Hospital Birmingham Outline 1. The burden of cancer after kidney transplantation 2. Epidemiology
More informationPostoperative monitoring after
Postoperative monitoring after kidney transplantation Bundit sakulchairungrueng,md Vascular and Transplantation Unit Faculty of Medicine Ramathibodi Hospital Mahidol University Reference Introduction A
More informationChapter 12. End Stage Kidney Disease in Indigenous Peoples of Australia and Aotearoa/New Zealand. ANZDATA Registry 39th Annual Report
Chapter 12 End Stage Kidney Disease in Indigenous Peoples of and Aotearoa/ 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Introduction In this chapter, the rates and practice patterns for end-stage
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationAustralia & New Zealand Pancreas. Transplant Registry Report
Australia & New Zealand Pancreas Transplant Registry Report 1984-2009 This report is a compilation of data provided by the three current Pancreas transplant units in Australia and New Zealand: Auckland
More informationCHAPTER 2 NEW PATIENTS COMMENCING TREATMENT IN 2007
CHAPTER 2 NEW PATIENTS COMMENCING TREATMENT IN 27 Stephen McDonald Leonie Excell Hannah Dent NEW PATIENTS ANZDATA Registry 28 Report Figure 2.1 Annual Intake of New Patients 23-27 (Number Per Million Population)
More informationCHAPTER 10 CANCER REPORT. Angela Webster Germaine Wong
CHAPTER 10 Angela Webster Germaine Wong ANZDATA Registry 2008 Report This year the cancer report contains results of a new ANZDATA analysis on survival after cancer diagnosis, and also shows how ANZDATA
More informationCHAPTER 3 DEATHS. Stephen McDonald Leonie Excell Brian Livingston
CHAPTER 3 DEATHS Stephen McDonald Leonie Excell Brian Livingston DEATHS ANZDATA Registry 2008 Report INTRODUCTION AUSTRALIA NEW ZEALAND The total number of deaths was 1,452 (15.4 deaths per 100 patient
More informationMORTALITY IN PATIENTS ON DIALYSIS AND TRANSPLANT RECIPIENTS
MORTALITY IN PATIENTS ON DIALYSIS AND TRANSPLANT RECIPIENTS COMPARISON OF MORTALITY IN ALL PATIENTS ON DIALYSIS, PATIENTS ON DIALYSIS AWAITING TRANSPLANTATION, AND RECIPIENTS OF A FIRST CADAVERIC TRANSPLANT
More informationManagement of a Recipient with a Failed Kidney Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
Management of a Recipient with a Failed Kidney Transplant Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Objectives Epidemiology of transplant failure Timing of dialysis
More informationTreated ESRD Incidence Rate for Selected Countries, New Patients/Million Pop. 250 USA (All) USRDS 1996
Annual Data Report International Comparisons of ESRD Therapy Chapter XI International Comparisons of ESRD Therapy O ver the last decade a growing number of national and regional registries dealing with
More informationEnd Stage Kidney Disease Among Indigenous Peoples of Australia and New Zealand
Chapter 12 End Stage Kidney Disease Among Indigenous Peoples of and New Zealand 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Introduction In this chapter, rates of end-stage kidney disease
More informationKidney Allograft Stone after Kidney Transplantation and its Association with Graft Survival
Original Article Kidney Allograft Stone after Kidney Transplantation and its Association with Graft Survival M. S. Rezaee-Zavareh 1,2, R. Ajudani 1, M. Ramezani Binabaj 1, F. Heydari 2, B. Einollahi 2
More informationTable S1. Clinical outcomes of the acceptable mismatch allocation model.
Table S1. Clinical outcomes of the acceptable mismatch allocation model. Recipient Age PRA Waiting Time (months) HLA mismatch (A/B/DR) HLAMatchmaker acceptable mismatch (years) (%) Actual Simulation Change
More informationKøbenhavns Universitet
university of copenhagen Københavns Universitet Survival Benefit in Renal Transplantation Despite High Comorbidity Sørensen, Vibeke Rømming; Heaf, James Goya; Wehberg, Sonja; Sørensen, Søren Schwartz Published
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationYoung Adults Program
Young Adults Program Project Title: Applicant: Primary contact: Secondary contact: Address: Kidney Health Australia Young Adults Program. Improving health outcomes post transition for adolescents and young
More informationSurgically Discovered Xanthogranulomatous Pyelonephritis Invading Inferior Vena Cava with Coexisting Renal Cell Carcinoma
Case Study TheScientificWorldJOURNAL (2009) 9, 5 9 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.6 Surgically Discovered Xanthogranulomatous Pyelonephritis Invading Inferior Vena Cava with Coexisting
More informationChapter 9. Kidney Donors. ANZDATA Registry 37th Annual Report. Data to 31-Dec-2013
Chapter 9 Kidney Donors 214 37th Annual Report Data to 31-Dec-213 9-2 Deceased Kidney Donors The data for this section come from the Australia and New Zealand Organ Donor (ANZOD) Registry. Much more information
More informationScores in kidney transplantation: How can we use them?
Scores in kidney transplantation: How can we use them? Actualités Néphrologiques 2017 M Hazzan (Lille France ) Contents Scores to estimate the quality of the graft Scores to estimate old candidates to
More informationShould Pediatric Patients Wait for HLA-DR-Matched Renal Transplants?
American Journal of Transplantation 2008; 8: 2056 2061 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationHeart Donation in Australia and New Zealand
Chapter 7 Heart Donation in Australia and New Zealand 2016 Annual Report Data to 31-Dec-2015 HEART DONATION In 2015, there were 95 heart transplant recipients, including two heart/double lung transplant
More informationChapter 2. Prevalence of End Stage Kidney Disease. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015
Chapter 2 Prevalence of End Stage Kidney Disease 2016 ANZDATA Registry 39th Annual Report Data to 31-Dec-2015 Renal Replacement Therapy Table 2.1 shows the prevalence (pmp) of renal replacement therapy
More informationUSRDS 1997 Annual Data Report International Comparisons of ESRD Therapy. Treated ESRD Incidence Rate for Selected Countries,
Annual Data Report International Comparisons of ESRD Therapy Chapter XII International Comparisons of ESRD Therapy Key Words: ESRD registry ESRD prevalence Dialysis modality Renal transplantation ESRD
More informationCHAPTER 10 CANCER REPORT. Germaine Wong Kirsten Howard Jonathan Craig Stephen McDonald Jeremy Chapman
CHAPTER 10 CANCER REPORT Germaine Wong Kirsten Howard Jonathan Craig Stephen McDonald Jeremy Chapman CANCER REPORT ANZDATA Registry 2006 Report INTRODUCTION RISK OF CANCERS IN KIDNEY DISEASES Notification
More informationManagement of a Recipient with a Failed Kidney Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
Management of a Recipient with a Failed Kidney Transplant Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Disclosures Grant support: Bristol-Myers and Squibb Pharmaceuticals,
More informationCHAPTER 4 METHOD AND LOCATION OF DIALYSIS. Nancy Briggs Kylie Hurst Stephen McDonald Annual Report 35th Edition
CHAPTER 4 METHOD AND LOCATION OF DIALYSIS Nancy Briggs Kylie Hurst Stephen McDonald 212 Annual Report 35th Edition METHOD AND LOCATION OF DIALYSIS ANZDATA Registry 212 Report AUSTRALIA Figure 4.1 Aust
More informationMalignancy UNGRADED SUGGESTIONS FOR CLINICAL CARE
Malignancy Date written: November 2011 Author: William Mulley GUIDELINES a. We recommend that screening for malignancy prior to ation be conducted in accordance with usual age and sex appropriate cancer
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationTransplant Options for Patients: Choices and Consequences. Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital
Transplant Options for Patients: Choices and Consequences Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital BC Kidney Days October 6 th 2017 Non contributory Conflict of
More informationChapter 15: Causes of Death on Renal Replacement Therapy
Chapter 15: Causes of Death on Renal Replacement Therapy Summary Cardiovascular disease is the most common cause of death in the renal population and is most evident in diabetics. Patients on renal replacement
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES
Specific management of IgA nephropathy: role of steroid therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Steroid therapy may protect against progressive
More informationCHAPTER 12 END-STAGE KIDNEY DISEASE AMONG INDIGENOUS PEOPLES OF AUSTRALIA AND NEW ZEALAND. Stephen McDonald. Matthew Jose. Kylie Hurst INDIGENOUS 12-1
ANZDATA Registry 213 Report INDIGENOUS END-STAGE KIDNEY DISEASE AMONG INDIGENOUS PEOPLES OF AUSTRALIA AND NEW ZEALAND CHAPTER 12 Stephen McDonald Matthew Jose Kylie Hurst 213 Annual Report - 36th Edition
More informationChapter 1. Incidence of End Stage Kidney Disease. Contents:
Chapter 1 Incidence of End Stage Kidney Disease Contents: Incidence of End Stage Kidney Disease 1-1 Stock and Flow 1-2 Incident patients 1-3 Incident Rates 1-3 Late Referral 1-7 Co-Morbidities 1-9 Primary
More informationDownloaded from ismj.bpums.ac.ir at 20: on Friday March 22nd 2019
- ( ) - -. :. ( ) :.. :... :. : // : -// : Email :Kazem_an@modares.ac.ir /..().(). ) (HLA.(). ( ) ( ). ) () ( ) ( () () () ( ). ().().().().().() (). / / / /..().. / / : (LDL). SPSS) SPSS STATA. (Inc,
More informationDiagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape
Diagnosis and Management of Acute and Chronic Humoral Rejection Lars Pape Immunosuppression Acute rejection Chronic rejection Side effects Infections Nephrotoxicity Adult population Nearly all late rejection-related
More informationTo watch a videotaped interview with this patient, visit clevelandclinic.org/transplant. clevelandclinic.org/transplant
SHARI MOSLEY KIDNEY TRANSPL ANT RECIPIENT Now that I have the transplant, I ve been given back my freedom. Shari Mosley, 23, Woodmere, Ohio. Seven years and one day after starting dialysis three times
More informationclevelandclinic.org/transplant
carolyn spiotta Pancreas/Kidney Transplant Recipient I feel so fortunate and thankful that I have received a second chance at life. Carolyn Spiotta, 44, Pittsburgh. Carolyn needed a new pancreas and kidney
More informationReviewer's report. Version:1Date:31 January Reviewer:IOANNIS LEOTSAKOS. Reviewer's report:
Reviewer's report Title:A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationWhy is the management of UTI so controversial? Kjell Tullus Consultant Paediatric Nephrologist
Why is the management of UTI so controversial? Kjell Tullus Consultant Paediatric Nephrologist Diagnosing a UTI More difficult then most people realise Contaminating culture Bacterial numbers Confusion
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationOrgan Waiting Lists in Australia and New Zealand
Chapter 7 Organ Waiting Lists in and New Zealand 2015 ANZOD Registry Annual Report Data to 31-Dec-2014 This chapter brings together waiting list data for the various organs. This data is not directly collected
More informationConcurrent Multilocular Cystic Renal Cell Carcinoma and Leiomyoma in the Same Kidney: Previously Unreported Association
218 Concurrent Multilocular Cystic Renal Cell Carcinoma and Leiomyoma in the Same Kidney: Previously Unreported Association Min Su Cheong a Dong Hun Koo a In-Sung Kim a Kyung Chul Moon b Ja Hyeon Ku a
More informationCHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping
CHAPTER 3 Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping Expert Panel: Tan Sri Dato Dr. Yahya Awang (Chair) Mr. Mohamed Ezani Hj Md. Taib (Co-chair) Datin Dr. Aziah Ahmad Mahayiddin
More informationPleiotropic effects of mtor inhibitors : cardiovascular and cancer. Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble
Pleiotropic effects of mtor inhibitors : cardiovascular and cancer Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble Tehran August 2016 Why this topic? Since last year very little news in the immunosuppressive
More informationAn epidemic of renal failure among Australian Aboriginals
emja Australia The Medical Journal of Home Issues emja shop Classifieds Contact More... Topics Search Login Buy full access An epidemic of renal failure among Australian Aboriginals Janine L Spencer, Desiree
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More informationIncidence and Predictors of Cancer Following Kidney Transplantation in Childhood
American Journal of Transplantation 2017; 17: 2650 2658 Wiley Periodicals Inc. 2017 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.14289 Incidence
More informationUpdate on Haematuria and Bladder Cancer
Update on Haematuria and Bladder Cancer Hugh Mostafid FRCS(urol) FEBU Consultant Urologist, Royal Surrey County Hospital and Honorary Senior Lecturer, University of Surrey Guildford None Declarations Recent
More informationCHAPTER 10 CANCER REPORT. Jeremy Chapman. and. Angela Webster
CHAPTER 10 CANCER REPORT Jeremy Chapman and Angela Webster CANCER REPORT ANZDATA Registry 2004 Report This report summarises the cancer (excluding nonmelanocytic skin cancer) experience of patients treated
More informationPatient and technique survival on peritoneal dialysis in patients with failed renal allograft: A case control study
http://www.kidney-international.org & 2006 International Society of Nephrology Patient and technique survival on peritoneal dialysis in patients with failed renal allograft: A case control study S Mujais
More informationFinal Report: Update on Prior Living Donors Who Were Subsequently Placed on the Waiting List
OPTN/UNOS Minority Affairs Committee Descriptive Data Request Final Report: Update on Prior Living Donors Who Were Subsequently Placed on the Waiting List Prepared for: Minority Affairs Committee Meeting
More informationLe migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE
Le migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE Best Therapy for Kidney Re- Transplantation? PREVENTION!!!! Registries CTS OPTN UNOS USRDS SRTR
More informationDoes Kidney Donor Risk Index implementation lead to the transplantation of more and higher-quality donor kidneys?
Nephrol Dial Transplant (2017) 32: 1934 1938 doi: 10.1093/ndt/gfx257 Advance Access publication 21 August 2017 Does Kidney Donor Risk Index implementation lead to the transplantation of more and higher-quality
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationCare of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary)
Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary) Bannon, F., Ranaghan, L., & Gavin, A. (2014). Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary). N. Cancer Registry,
More informationJ Am Soc Nephrol 14: , 2003
J Am Soc Nephrol 14: 208 213, 2003 Kidney Allograft and Patient Survival in Type I Diabetic Recipients of Cadaveric Kidney Alone Versus Simultaneous Pancreas/Kidney Transplants: A Multivariate Analysis
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More information